Breaking News, Collaborations & Alliances

Novartis, ProBioGen Ink GlymaxX ADCC Tech Pact

Will apply GlymaxX ADCC to manufacture antibodies in preclinical and clinical development

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen AG has signed a non-exclusive, multi-product licensing agreement with Novartis for its GlymaxX Antibody Glyco-Engineering technology. Novartis will apply the technology for the manufacture of selected ADCC activity-enhanced (Antibody-Dependent Cell-Mediated Cytotoxicity) antibodies in preclinical and clinical development. Financial terms were not disclosed.   The GlymaxX technology can be applied to both novel and already existing antibody producer cell lines, as well as to entire prod...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters